XENE vs. CTLT, SRPT, QGEN, PCVX, ASND, ROIV, RVMD, LNTH, BPMC, and BBIO
Should you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.
Xenon Pharmaceuticals vs.
Catalent (NYSE:CTLT) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
Xenon Pharmaceuticals has a net margin of 0.00% compared to Catalent's net margin of -9.28%. Catalent's return on equity of -0.66% beat Xenon Pharmaceuticals' return on equity.
Catalent received 221 more outperform votes than Xenon Pharmaceuticals when rated by MarketBeat users. However, 69.95% of users gave Xenon Pharmaceuticals an outperform vote while only 57.50% of users gave Catalent an outperform vote.
Xenon Pharmaceuticals has lower revenue, but higher earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 0.3% of Catalent shares are held by insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than Catalent. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 1 mentions for Catalent. Xenon Pharmaceuticals' average media sentiment score of 1.04 beat Catalent's score of 0.28 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.
Catalent has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Catalent presently has a consensus price target of $63.40, indicating a potential downside of 0.13%. Xenon Pharmaceuticals has a consensus price target of $56.00, indicating a potential upside of 45.38%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Catalent.
Summary
Xenon Pharmaceuticals beats Catalent on 14 of the 19 factors compared between the two stocks.
Get Xenon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xenon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:XENE) was last updated on 1/20/2025 by MarketBeat.com Staff
Free XENE Stock Alerts